cho_logo_symbol_border
  • (800) 266-7207 | 30 Wall St. 8th Floor New York, NY 10005
  • Mon - Fri: 8:00 am - 5:00 pm

Day: September 8, 2022

New Omicron offshoot BA.4.6 evades protection of Evusheld’s antibodies, study finds

139 Views0 Comments

(CNN) – “The antibodies in Evusheld, the only therapy available to protect people with reduced immune function against Covid-19, may lose their punch against the BA.4.6 subvariant, a new study shows. BA.4.6 is an offshoot of the BA.4 subvariant of the Omicron coronavirus variant. Only a couple

Read More

Disclaimer

Clear Health Pass Safe Harbor Exemption
The information on this website does not constitute an offer to sell or solicitation of an offer to buy securities by anyone in any jurisdiction which would be considered unlawful. Clear Health Pass Holdings, LLC’s offering is under Rule 506(c) of Regulation D and is considered a “safe harbor” for the private offering exemption of Section 4(a)(2) of the Securities Act. To be eligible to receive qualified investment status, you must be an accredited investor as defined by Section 2(15)(ii) of the Securities Act of 1933.

© 2023 Clear Health Pass Holdings™, LLC., All trademark references are trademarks of either the Clear Health Pass Holdings, LLC or their respective owners.

 

Our Journey to $1B+ Valuation

 

Disrupting Healthcare Testing / Diagnostics Early Detection of Cancer,
Chronic Conditions, Disease, Unlocking Anti-Aging Genomics & Promoting Longevity.

 

FUNDING GOAL $20,000,000

Funding Goal $20,000,000

20%

Click here to Download Our Investment Package

Skip to content